San DiegoBiotechnologyHealthcareMedicalTherapeuticsPharmaceuticalresearch
Description
Zentalis Pharmaceuticals is making changes to its executive team, with the appointment of a new CEO and chief medical officer. Julie Eastland, former CEO of Merck-acquired Harpoon Therapeutics, will take over as CEO, while experienced oncology executive Ingmar Bruns, M.D., Ph.D., has been selected as the new chief medical officer.
Company Information
Company
Zentalis Pharmaceuticals
Location
10275 Science Center Dr
San Diego, California, United States
About
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC.
Fundz sees it the moment Zentalis Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealthcareMedicalTherapeuticsPharmaceuticalresearch